- Full Title: "Effectiveness of whole virus COVID-19 vaccine at protecting health care personnel against
 SARS-CoV-2 infections in Lima, Peru"
- 34 Short Title: "Whole virus vaccine effectiveness among healthcare personnel"
- 5
- 6 Authors:
- 7 Carmen S Arriola¹, Giselle Soto², Matthew Westercamp³, Susan Bollinger³, Angelica Espinoza², Max
- 8 Grogl², Alejandro Llanos-Cuentas⁴, Eduardo Matos⁵, Candice Romero², Maria Silva², Rachel Smith³,
- 9 Natalie Olson¹, Michael Prouty², Eduardo Azziz-Baumgartner¹, Fernanda C. Lessa³
- 10 Affiliations:
- ¹Centers for Disease Control and Prevention, Influenza Division, National Center for Immunization and
- 12 Respiratory Diseases (NCIRD), Atlanta, Georgia, USA
- ² Naval Medical Research Unit No 6 (NAMRU-6), Lima, Peru
- ³Centers for Disease Control and Prevention, Division of Healthcare Quality and Promotion, National
- 15 Center for Emerging and Zoonotic Infectious Diseases (NCEZID), Atlanta, Georgia, USA
- ⁴Cayetano Heredia Hospital, Lima, Peru
- ⁵ Arzobispo Loayza National Hospital, Lima, Peru
- 18

19 Corresponding Author: Carmen Sofia Arriola, Influenza Division, Centers for Disease Control and

20 Prevention, 1600 Clifton Rd MS A-32, Atlanta, GA 30329, United States; telephone: (404) 718-4589;

- 21 fax (404) 639-3866; email: wus3@cdc.gov.
- 22

23 Abstract (300w)

24

In February 2021, Peru launched a vaccination campaign among healthcare personnel using BBIBP CorV inactivated whole virus (BBIBP-CorV) COVID-19 vaccine. Two doses of BBIBP-CorV vaccine

are recommended, 21 days apart. Data on BBIBP-CorV vaccine effectiveness will inform the use and acceptance of vaccination with BBIBP-CorV vaccine.

29

We evaluated BBIBP-CorV vaccine effectiveness among an existing multi-year influenza cohort at two

hospitals in Lima. We analyzed data on 290 participants followed between February and May 2021.
 Participants complete discharged in the section.

Participants completed a baseline questionnaire and provided weekly self-collected anterior nasal swabs tested for SARS-CoV-2 by rRT-PCR for sixteen weeks. We performed multivariable logistic regression models adjusting for pre-selected characteristics (age, ser, expensive to COVID, 10 performed multivariable logistic regression)

models adjusting for pre-selected characteristics (age, sex, exposure to COVID-19 patients, work in
 intensive care unit or emergency department, BMI, and exposure time in days). BBIBP-CorV vaccine
 effectiveness was calculated after the two-week post-vaccination period as (1-Odds Ratio for testing
 SARS-CoV-2 positive)x100%.

38

SARS-CoV-2 was detected by rRT-PCR among 25 (9%) participants during follow-up (February-May
2021). Follow-up period ranged 1-11 weeks (median: 2 weeks). Among cohort participants who were
fully vaccinated the adjusted vaccine effectiveness against SARS-CoV-2 infection was estimated as 95%
(95% CI: 70%, 99%) and 100% (95% CI: 88%, 100%) for those partially vaccinated.

43

44 During the study period, vaccination of healthcare personnel with BBIBP-CorV vaccine was effective at

- 45 reducing SARS-CoV-2 infections in the weeks immediately following vaccination. This information can
- 46 be used to support vaccination efforts in the region, especially among those who could be concerned
- 47 about their effectiveness.

48

49 Introduction

50

51 Peru is a middle-income country (MIC) disproportionately affected by coronavirus disease (COVID-19) 52 and struggling to protect its essential workforce [1-4]. Despite early lockdowns, curfews, and other 53 public health and social measures implemented to reduce disease spread [5], as of May 22, 2021, Peru 54 had reported 180,764 COVID-19 associated deaths [6], and continues to accrue cases [7]. As in many 55 other MICs, healthcare services have been overwhelmed with patients, have limited personal protective 56 equipment, and have delayed and limited COVID-19 vaccination, leading to unrest and strikes among 57 Peruvian healthcare personnel [8]. COVID-19 vaccination with Sinopharm BBIBP-CorV (Beijing 58 Institute of Biological Products Coronavirus Vaccine) inactivated whole virus vaccine, hereinafter 59 referred to as BBIBP-CorV vaccine, was initiated in Peru on February 9, 2021, with healthcare personnel as a priority group for vaccination. During the study period (February 9 to May 4, 2021). 60 61 BBIBP-CorV vaccine was the only COVID-19 vaccine available in Peru for healthcare personnel [9, 62 10]. Two doses of BBIBP-CorV vaccine are recommended, 21 days apart. To date, BBIBP-CorV vaccine effectiveness data against SARS-CoV-2 infection have not been published in the peer-reviewed 63 64 literature. Evidence on BBIBP-CorV vaccine effectiveness could reduce hesitancy about the vaccine and would support vaccination efforts. We leveraged an existing multi-year influenza cohort of healthcare 65 workers at two Lima hospitals [11] to evaluate BBIBP-CorV vaccine effectiveness at preventing both 66

- 67 symptomatic and asymptomatic SARS-CoV-2 infections during the study period.68
- 69 Methods
- 70
- 71 Study design

From the start of COVID-19 vaccination among healthcare personnel on February 9, 2021 until May 4,

73 2021, we followed healthcare personnel aged 18 to 65 years who were participating in an ongoing

cohort of healthcare workers at two tertiary referral hospitals in Lima [11]. Inclusion criteria for cohort

eligibility were: age ≥ 18 years; work at the facility full-time (≥ 30 hours per week); have routine, direct,

hands-on or face-to-face contact with patients (within 1 meter) as part of a typical work shift; and have

77 worked at the facility for ≥ 1 year prior to enrollment.

78

79 Between November 25, 2020, and January 9, 2021, participants provided written informed consent and

- completed a baseline questionnaire about their demographics and role in the hospital (self-report
 exposure to COVID-19 patients (yes/no), work in intensive care unit (ICU) (yes/no), emergency
- 82 department (ED) (yes/no)). Participants provided serum samples at baseline and at the end of the study
- 83 period. Each participant was followed for 16 weeks after enrollment. Participants responded to a weekly
- survey that included questions about COVID-19 exposure and receipt of BBIBP-CorV vaccine
- survey that included questions about COVID-19 exposure and receipt of BBIBP-CorV vaccine
 (documented by the hospitals). Participants also provided a weekly self-collected anterior nasal swab
- 86 which was tested for SARS-CoV-2 by real-time reverse transcription polymerase chain reaction (rRT-
- 87 PCR) at the Naval Medical Research Unit 6 (NAMRU-6) in Lima, following Centers for Disease
- 88 Control and Prevention (CDC) testing protocols [12]. rRT-PCR testing was performed in pools of five
- samples; if positive, all five individual samples were tested separately. Serum samples were shipped to
- the CDC in Atlanta, Georgia, United States of America, for pan-Ig serology testing [13].
- 91
- 92 Statistical analysis

93 We described healthcare personnel demographics, occupational information, baseline serology, COVID-

94 19 vaccine receipt and laboratory detection of SARS-CoV-2. We applied Chi-square or Wilcoxon tests,

- 95 as appropriate, to assess differences in demographics, occupational information, and baseline serology, 96 stratified by SARS-CoV-2 detection and COVID-19 vaccine receipt. 97 98 We estimated vaccine effectiveness using a multivariable logistic regression model adjusted for pre-99 selected characteristics [i.e., age, sex, exposure to COVID-19 patients, work in ICU, ED, body mass index (BMI), and time of follow-up in days] and presented vaccine effectiveness estimates [(1-Odds 100 101 Ratio) x100%] with 95% confidence intervals (CI). For these analyses, we excluded those who were 102 seropositive at baseline and those with a positive COVID-19 test before February 9, 2021. We defined 103 full vaccination as the period starting 14 days after receipt of the second dose and partial vaccination as 104 the period starting 14 days after receipt of the first dose. Participants not meeting these criteria were 105 considered unvaccinated. The partial vaccination model only included those who received one dose of 106 the vaccine during the study period. Partially vaccinated individuals were excluded from the full 107 vaccination analysis. COVID-19 vaccine effectiveness was calculated under both full and partial vaccination scenarios. The outcome of interest in the model was SARS-CoV-2 detection; if SARS-CoV-108 109 2 was detected in an individual before first vaccination date or before the two-week period after first vaccination, he/she would be considered unvaccinated for the analysis. All analyses were conducted in R 110 111 (R version 4.1.0). 112 113 **Ethics** 114 This study was reviewed and approved by the NAMRU6 IRB as the single IRB (sIRB) for this study[§]. 115 116 Results Study sample characteristics, SARS-CoV-2 infections and COVID-19 vaccine receipt 117 118 Two hundred and ninety cohort participants were followed between February 9 and May 4, 2021, of 119 which 270 (93.1%) reported receiving at least one dose of COVID-19 vaccine; of these, 80% (216/270)
- reported being fully vaccinated before the end of follow-up. The follow-up period after vaccination
- ranged 1-11 weeks after the two-week post-vaccination period; median of 2 weeks. Median age of participants was 45 years (IQR: 38, 52). Three out of four (74%; 215/290) participants were female and
- participants was 45 years (IQK, 58, 52). Three out of four (74%, 215/290) participants were remare and
 90% (260/290) reported being of mixed race. Only 3% (8/290) reported a chronic medical condition,
- 124 including asthma, diabetes, high blood pressure, chronic heart disease, autoimmune condition,
- 125 HIV/AIDS, or other medical condition requiring clinical care for at least 6 months. Of 290 participants,
- 126 49% (n=143) were classified as overweight and 22% (n=64) as obese. One third (106/290) of
- 127 participants' baseline sera had a reactive result for SARS-CoV-2 pan-Ig antibodies, and SARS-CoV-2
- 128 was detected by rRT-PCR among 25 (9%) participants during follow-up. Those seronegative at baseline
- were more likely to subsequently test positive for SARS-CoV-2 through rRT-PCR than those
 seropositive at baseline (p-value<0.001; Table 1).
- 131
- 132 COVID-19 vaccine effectiveness
- After excluding those seropositive at baseline and those with a positive COVID-19 test before February 9, 2021, and adjusting for age, sex, exposure to COVID-19 patients, work in ICU, work in ED, BMI,
- and time of follow-up in days, COVID-19 vaccine effectiveness against SARS-CoV-2 infection (either
- symptomatic or asymptomatic) was estimated as 97% (95% CI: 88%, 99%) for those who received at
- least one dose of the vaccine; 100% (95% CI: 88%, 100%) for those partially vaccinated, and 95% (95%
 CI: 70%, 99%) for those fully vaccinated (Table 2).
 - [§] See 45 C.F.R. part 46.114; 21 C.F.R. part 56.114

139

140 Discussion

141

142 Among those vaccinated in this cohort, we estimate BBIBP-CorV vaccine was \geq 90% effective in

- 143 preventing infection with SARS-CoV-2 in the weeks immediately following vaccination. To our
- knowledge, this is the first peer-reviewed data of BBIBP-CorV vaccine effectiveness against SARS-
- 145 CoV-2 infection. Furthermore, our findings indicate that during the study period (February to May
- 146 2021), one in ten study participants in two tertiary hospitals in Lima were infected with laboratory-
- 147 confirmed SARS-CoV-2.
- 148 Healthcare personnel are at increased risk of becoming infected with SARS-CoV-2 [14]. Our findings
- show continued detection of SARS-CoV-2 infection during the study period. In Peru, it is estimated that
- >600 physicians and nurses have died of COVID-19 through June 2021 [1]. Protecting the healthcare
 workforce is a global priority to ensure delivery of healthcare to the population. The World Health
- 152 Organization (WHO) Strategic Advisory Group of Experts on Immunization (SAGE) roadmap for
- prioritizing use of COVID-19 vaccines in the context of limited supplies includes healthcare personnel
- as one of the highest priority groups for vaccination [15]. The government of Peru initiated their
- 155 COVID-19 vaccination on February 9, 2021, with healthcare personnel being the initial targeted group
- 156 to receive the vaccine [16].
- 157 Our study indicates the BBIBP-CorV vaccine is effective against SARS-CoV-2 infection in the
- 158 immediate period after vaccination. Our findings are compatible with those reported by WHO where
- 159 BBIBP-CorV vaccine efficacy was estimated as 78.9% (95% CI: 65.8%-87%) against COVID-19
- 160 disease in an unpublished clinical trial, with a follow-up time of two months [17]. Furthermore, our
- 161 findings are consistent with interim estimates published by WHO, which estimated that vaccine
- 162 effectiveness against rt-PCR confirmed cases among adults 18 years of age and older in Bahrain was
- 163 90% (95% CI: 88%, 91%) [18].
- 164 In our study, we suspect that B.1.1.1 was the dominant circulating variant in early 2021, as it was
- 165 detected in 43% of the samples that were sequenced (n=23). However, SARS-CoV-2 variant P.1 was
- identified for the first time in Peru in January 2021 [19] and P.1 was identified in one out of 19 samples
 that were collected in January and February 2021 (data not shown); this strain emerged in Brazil in mid-
- 168 November and rapidly spread in the state of Amazonas in early 2021, causing several hospitalizations
- and deaths [20, 21]. WHO included P.1 as one of four variants of concern in January 2021 because of its
- 170 increased transmissibility and virulence [22]. It is important to maintain data collection over time to
- 171 assess vaccine effectiveness under real-life circumstances while new variants circulate.
- 172 Due to high COVID-19 morbidity and mortality, BBIBP-CorV vaccine was rolled out in Peru and
- 173 numerous other countries despite not having robust effectiveness data [23]. Though long-term
- effectiveness data are still needed, the results from our study support BBIBP-CorV's continued use, at
- 175 least in the absence of available vaccines with proven long-term effectiveness. Data from this study can
- be used to support vaccination in the region; presenting vaccine effectiveness data can improve vaccine
- 177 uptake [24]. Unlike some other COVID-19 vaccines, BBIBP-CorV has the advantage that it does not
- 178 require complicated cold chain logistics, such as ultralow freezer conditions; instead, it can be used
- 179 within the existing cold chain infrastructure of national immunization programs [25].
- 180 This study had several noteworthy strengths. This prospective cohort study was rapidly implemented by
- 181 leveraging an ongoing prospective cohort established to evaluate influenza vaccine effectiveness among
- 182 healthcare personnel with weekly swabbing and testing for SARS-CoV-2, regardless of symptoms. This
- 183 frequency and breadth of sampling among our cohort allowed for greater detection of infection than in

- passive surveillance systems. Participation rate in this COVID-19 study was high (85%) and remained
- high throughout the 16-week follow-up period (>96% of participants submitted specimens in at least 13
- of the 16 weeks of follow-up). SARS-CoV-2 infection was confirmed through rRT-PCR in NAMRU-6's
- 187 high proficiency laboratory, following CDC's SARS-CoV-2 diagnostic protocol, and did not rely on
- 188 point of care testing with less sensitive assays.
- 189 This study had at least four limitations. The high vaccine effectiveness we observed may be related to
- 190 the short follow-up period after vaccination (range: 1-11 weeks after the two-week post-vaccination
- 191 period; median of 2 weeks); a longer follow-up period is necessary to fully evaluate the long-term
- 192 effectiveness of the vaccine among this study population. In addition, the study was not sufficiently
- 193 powered to stratify VE estimates by variant or symptomatic vs asymptomatic infection. Moreover,
- because of the limited availability of laboratory staff and high volume of weekly respiratory specimens,
- 195 we implemented a pooling strategy for SARS-CoV-2 testing which may have decreased sensitivity to
- 196 detect those with low viral shedding. Last, our study could not distinguish nasal carriage of the virus
- 197 from lower respiratory tract infection.
- 198 In summary, one in ten healthcare personnel in our study in Peru tested positive for SARS-CoV-2 during
- 199 February to May 2021. Vaccination of healthcare personnel with BBIBP-CorV vaccine was effective at
- 200 reducing SARS-CoV-2 infections in the weeks immediately following vaccination. The data presented
- 201 in this study supports the Peruvian Government's ongoing COVID-19 vaccination efforts for reducing
- 202 SARS-CoV-2 infections, especially among this critical workforce of healthcare professionals.
- 203
- 204
- 205
- 206
- 207
- 207

208 Disclaimer

- 209 The findings and conclusions in this report are those of the authors and do not necessarily represent the
- 210 views of the US Centers for Disease Control and Prevention, the Department of the Navy, Department
- 211 of Defense, nor the US Government.
- 212
- 213 Acknowledgments
- 214 We thank the participants who enrolled in the study; Nia Mims for the establishment of the CDC-DOD
- 215 Interagency Agreement; the International Reagent Resource Team at CDC, Influenza Division; the CDC
- 216 COVID-19 response teams: International Task Force, Laboratory Task Force. We also thank Miriam
- 217 Gonzalez and Sayda La Rosa for supervision and work with field workers collecting data and samples;
- 218 Fiorela Alvarez and Rocio Mananita for their clinical support during surveillance activities; NAMRU-6
- 219 Laboratory Team, LCDR Paul Graf, LCDR Stephen Lizewski, LT Eugenio Abente, Roger Castillo,
- Anilu Tecco, for their extraordinary support and hard work processing samples; Vicky Arnao for
- administrative support.
- 222223 Financial Disclosure
- The study was funded through CDC Interagency Agreement 19FED1916949IPD.
- 225
- 226 The study protocol was approved by the U.S. Naval Medical Research Unit 6 (NAMRU-6) Institutional
- Review Board in compliance with all applicable federal regulations governing the protection of humansubjects.
- 229
- 230 Copyright Statement
- I am a federal employee of the United States government. This work was prepared as part of my official
- duties. Title 17 U.S.C. 105 provides that `copyright protection under this title is not available for any
- work of the United States Government.' Title 17 U.S.C. 101 defines a U.S. Government work as work
- prepared by a military service member or employee of the U.S. Government as part of that person's
- 235 official duties.
- 236
- 237 Competing interests
- 238 All authors report no potential conflicts.
- 239
- 240 241

242 243 244	Refer	ences
244 245 246 247	1.	Colegio Medico del Peru. <i>Medicos fallecidos for covid-19 en Iberoamerica</i> . 2021 [cited 2021 June 27th]; Available from: <u>https://www.cmp.org.pe/medicos-fallecidos-por-covid-19-en-iberoamerica/</u> .
248	2.	Fraser, B., COVID-19 strains remote regions of Peru. Lancet, 2020. 395(10238): p. 1684.
249 250 251	3.	Alvarez-Risco, A., C.R. Mejia, J. Delgado-Zegarra, S. Del-Aguila-Arcentales, et al., <i>The Peru Approach against the COVID-19 Infodemic: Insights and Strategies</i> . Am J Trop Med Hyg, 2020. 103 (2): p. 583-586.
252 253	4.	Munayco, C., G. Chowell, A. Tariq, E.A. Undurraga, et al., <i>Risk of death by age and gender from CoVID-19 in Peru, March-May, 2020.</i> Aging (Albany NY), 2020. 12 (14): p. 13869-13881.
254 255	5.	Calderon-Anyosa, R.J.C. and J.S. Kaufman, Impact of COVID-19 lockdown policy on homicide, suicide, and motor vehicle deaths in Peru. Prev Med, 2021. 143: p. 106331.
256 257 258	6.	Pan American Health Organization. <i>COVID-19 Region of the Americas Update</i> . 2021 [cited 2021 June 27th]; Available from: <u>https://iris.paho.org/bitstream/handle/10665.2/54325/COVID-19DailyUpdate17June2021_eng.pdf?sequence=1&isAllowed=y</u> .
259 260	7.	World Health Organization. <i>WHO Coronavirus (COVID-19) Dashboard</i> . [cited 2021 June 26th]; Available from: <u>https://covid19.who.int/region/amro/country/pe/</u> .
261 262 263	8.	REUTERS. <i>Médicos en Perú se declaran en huelga de hambre por más inversión en salud en plena segunda ola.</i> 2021 [cited 2021 June 27th]; Available from: <u>https://www.reuters.com/article/salud-coronavirus-peru-huelga-idLTAKBN2902R7</u> .
264 265 266	9.	Government of Peru. <i>Resolución Ministerial N°</i> 848-2020-MINSA. Plan Nacional de Vacunación contra la COVID-19. 2020 [cited 2021 June 26th]; Available from: <u>https://www.gob.pe/institucion/minsa/normas-legales/1293043-848-2020-minsa</u> .
267 268 269 270	10.	Government of Peru. <i>Resolución Ministerial N° 023-2021-MINSA. CENARES se encargue de ejecutar el Acuerdo de Compraventa con la empresa SINOPHARM.</i> 2021 [cited 2021 June 26th]; Available from: <u>https://www.gob.pe/institucion/minsa/normas-legales/1475842-023-2021-minsa</u> .
271 272 273	11.	Wesley, M.G., G. Soto, C.S. Arriola, M. Gonzales, et al., <i>Prospective cohort study of influenza vaccine effectiveness among healthcare personnel in Lima, Peru: Estudio Vacuna de Influenza Peru, 2016-2018.</i> Influenza Other Respir Viruses, 2020. 14 (4): p. 391-402.
274 275 276	12.	CDC. <i>CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel</i> . Last updated 12/01/2020 [cited 2021 June 26th]; Available from: <u>https://www.fda.gov/media/134922/download</u> .
277 278	13.	Freeman, B., S. Lester, L. Mills, M.A.U. Rasheed, et al., <i>Validation of a SARS-CoV-2 spike protein ELISA for use in contact investigations and serosurveillance</i> . bioRxiv, 2020.

- 14. Nguyen, L.H., D.A. Drew, M.S. Graham, A.D. Joshi, et al., *Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study.* Lancet Public
 Health, 2020. 5(9): p. e475-e483.
- 15. World Health Organization. WHO SAGE Roadmap For Prioritizing Uses Of COVID-19
 Vaccines In The Context Of Limited Supply. 2020 [cited 2021 July 6th]; Available from:
 https://www.who.int/publications/i/item/who-sage-roadmap-for-prioritizing-uses-of-covid-19 vaccines-in-the-context-of-limited-supply.
- REUTERS. 'The best shield': Peru launches inoculation drive with Sinopharm vaccine. 2021
 [cited 2021 June 27th]; Available from: <u>https://www.reuters.com/business/healthcare-</u>
 pharmaceuticals/the-best-shield-peru-launches-inoculation-drive-with-sinopharm-vaccine-2021 02-10/.
- World Health Organization. Annexes to the interim recommendations for use of the inactivated
 COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm 2021
 [cited 2021 July 6th]; Available from: https://apps.who.int/iris/handle/10665/347768.
- 18. World Health Organization. *Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine*. 2021
 [cited 2021 June 27th]; Available from: <u>https://cdn.who.int/media/docs/default-</u>
 source/immunization/sage/2021/april/2_sage29apr2021_critical-evidence_sinopharm.pdf.
- 19. Ministerio de Salud del Peru. *INS detectó la presencia de la variante brasileña del coronavirus en Loreto, Huánuco y Lima.* 2021 [cited 2021 June 27th]; Available from: <u>https://web.ins.gob.pe/es/prensa/noticia/ins-detecto-la-presencia-de-la-variante-brasilena-del-</u> 299 <u>coronavirus-en-loreto-huanuco</u>.
- Faria, N.R., T.A. Mellan, C. Whittaker, I.M. Claro, et al., *Genomics and epidemiology of a novel SARS-CoV-2 lineage in Manaus, Brazil.* medRxiv, 2021.
- 302 21. Naveca, F.G., V. Nascimento, V.C. de Souza, A.L. Corado, et al., *COVID-19 in Amazonas*,
 303 *Brazil, was driven by the persistence of endemic lineages and P.1 emergence*. Nat Med, 2021.
- World Health Organization. *Tracking SARS-CoV-2 variants*. 2021 [cited 2021 July 6th];
 Available from: <u>https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</u>.
- 30623.Pan American Health Organization. COVID-19 Vaccination in the Americas. 2021 [cited 2021307July 19th]; Available from: https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion.asp.
- Kaplan, R.M. and A. Milstein, *Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance.* Proc Natl Acad Sci U S A, 2021. 118(10).
- Acharya, K.P., T.R. Ghimire, and S.H. Subramanya, Access to and equitable distribution of
 COVID-19 vaccine in low-income countries. NPJ Vaccines, 2021. 6(1): p. 54.
- 312
- 313
- 314
- 315

Tables & Figures

Table 1: Demographic, occupational information, baseline serology, COVID-19 vaccine receipt and laboratory detection of SARS	-
CoV-2 among healthcare personnel cohort participants, Lima-Peru, February 9 to May 4, 2021, N=290	

	Total	SARS-CoV- 2 positive *	SARS-CoV-2 negative	p-value□	Unvaccinated	Partially vaccinated**	p-value□	Fully vaccinated**	p-value□
	N=290 (100%)	n=25 (9%)	n=265 (91%)		n=20 (7%)	n=54 (19%)		n=216 (74%)	
Age (years)									
Median (IQR)	45 (38,52)	48 (41, 54)	45 (38,51)		39 (37,49)	47 (39, 52)		45 (39,52)	
18-39	85 (29)	6 (24)	79 (30)	0.82	10 (50)	14 (26)	0.14	61 (28)	0.12
40-49	110 (38)	10 (40)	100 (38)	0.82	5 (25)	22 (41)	0.14	83 (38)	0.12
50-65	95 (33)	9 (36)	86 (32)		5 (25)	18 (33)		72 (33)	
Gender									
Male	75 (26)	6 (24)	69 (26)	1.0	1 (5)	25 (46)	-0.01	49 (23)	0.12
Female	215 (74)	10 (76)	196 (74)	1.0	19 (95)	29 (54)	< 0.01	167 (77)	0.12
Race/Ethnicity									
Mixed race	260 (90)	21 (84)	239 (90)		19 (95)	45 (83)		196 (91)	
Indigenous	19 (7)	2 (8)	17 (6)	0.45	1 (5)	3 (6)	0.40	15 (7)	0.00
Black	8 (3)	1 (4)	7 (3)	0.45	0 (0)	5 (9)	0.48	3 (1)	0.89
White	3 (1)	1 (4)	2 (1)		0 (0)	1 (2)		2 (1)	
Education									
High school education only	37 (13)	2 (8)	35 (13)		0 (0)	13 (24)		24 (11)	
Associate degree from college or equivalent/Bach elor's degree	233 (80)	21 (84)	212 (80)	0.75	20 (100)	38 (70)	0.02	175 (81)	0.10
Postgraduate education	20 (7)	2 (8)	18 (7)		0 (0)	3 (6)		17 (8)	
Comorbidities									
Any medical condition**	8 (3)	2 (8)	6 (2)	0.52	1 (5)	2 (4)	0.74	5 (2)	0.64
BMI									

Normal (18.5 to <25)	83 (29)	9 (36)	74 (28)		9 (45)	17 (31)		57 (26)	
Overweight (25 to <30)	143 (49)	12 (48)	131 (49)	0.61	7 (35)	27 (50)	0.47	109 (50)	0.20
Obese (≥30)	64 (22)	4 (16)	60 (23)		4 (20)	10 (19)		50 (23)	
moking daily/some)	11 (4)	1 (4)	10 (4)	1.0	1 (5)	3 (6)	1.0	7 (3)	1.0
ob type									
Physician	11 (4)	1 (4)	10 (4)		0 (0)	0 (0)		11 (5)	
Nurse	63 (22)	2 (8)	61 (23)		1 (5)	10 (19)		52 (24)	
Midwife/Dentist	12 (4)	1 (4)	11 (4)		0 (0)	0 (0)		12 (5)	
Technician/assist ant	135 (47)	14 (56)	121 (46)		15 (75)	17 (31)		103 (48)	
Pharmacist/socia									
1	2(1)	0 (0)	2(1)	0.62	1 (5)	0 (0)	< 0.01	1 (0)	0.08
worker/nutritioni	2(1)	0(0)	2(1)	0.62	1 (5)	0(0)	<0.01	1(0)	0.08
st									
Physical	4(1)	0 (0)	4 (2)		0 (0)	2 (4)		2(1)	
therapist	4(1)	0(0)	4 (2)		0(0)	2 (4)		2(1)	
Admin/security/									
maintenance/Tra	49 (17)	7 (28)	42 (15)		1 (5)	20 (37)		28 (12)	
nsporter									
Other	14 (5)	0 (0)	14 (5)		2 (10)	5 (9)		7 (3)	
xposed to COVID-									
9 Patients in	249 (86)	18 (72)	231 (87)	0.59	17 (85)	45 (83)	1.0	187 (87)	1.0
ealthcare setting									
/ork in ICU	27 (9)	4 (16)	23 (9)	0.40	0 (0)	8 (15)	0.16	19 (9)	0.34
Vork in Emergency	101 (35)	11 (44)	90 (34)	0.43	9 (45)	20 (37)	0.72	72 (33)	0.42
epartment	101 (55)	11 (44)	90 (34)		9 (43)	20 (37)		12 (55)	
umber of work									
ours at site per	36 (36,36)	36 (36,40)	36 (36,36)	0.93	36 (36,39)	36 (36,48)	0.23	36 (36,36)	0.40
eek (median, IQR)									
umber of patient-									
rovider face-to-	30 (24,36)	30 (20,30)	30 (25,36)	0.04	33 (30,37)	30 (25,36)	0.31	30 (24,36)	0.11
ice hours per week	20 (_ 1,20)	20 (20,20)	20 (20,00)	0.01	22 (20,07)	20 (20,00)	0.01	20 (21,20)	5.11
nedian, IQR)									
eactive SARS-	106 (27)	0.(0)	106 (10)	0.001	5 (05)	15 (20)	1.0		0.00
CoV-2 serology at	106 (37)	0 (0)	106 (40)	< 0.001	5 (25)	15 (28)	1.0	86 (40)	0.28
aseline									

Notes:

* At least once by weekly testing during follow-up period

**Vaccination of healthcare workers started in Lima on February 9, 2021 and was assessed by interview on a weekly basis. Partially vaccinated refers to those who received 1 dose of whole virus COVID-19 vaccine during the study period; fully vaccinated refers to those who received 2 doses of whole virus COVID-19 vaccine during the study period

***Asthma, diabetes, high blood pressure, chronic heart disease, autoimmune condition, HIV/AIDS, another medical condition requiring clinical care for at least 6 months

Chi-square test for categorical and Wilcoxon signed rank test for continuous variables. Partially and fully vaccinated groups were compared to unvaccinated individuals, separately

Table 2. COVID-19 vaccine effectiveness (VE) by dose received among healthcare personnel cohort participants, Lima-Peru, February 9 to May 4, 2021

	COVIE	0-19 Cases	Co	ntrols	Unadjusted VE	Adjusted VE* % (95% CI)	
-	Vaccinated	Unvaccinated	Vaccinated	Unvaccinated	% (95% CI)		
Received at least one dose of vaccine	10	9	138	6	95% (84%, 99%)	97% (88%, 99%)	
Fully vaccinated	5	9	36	6	91% (63%, 98%)	95% (70%, 99%)	
Partially vaccinated	5	9	25	6	87% (45%, 97%)	100% (88%, 100%)	

*Adjusted for age, sex, exposure to COVID-19 patients, work in ICU, work in ER, BMI, and time of follow-up.

Note1: Those with reactive SARS-CoV-2 serology at baseline have been excluded (n=106).

Note2: Those with a positive COVID-19 test before February 9, 2021 have been excluded (n=17).

Note3: Those who had tested positive before vaccination date or before the 2-week period after vaccination were considered unvaccinated for the model.

Note 4: We defined full vaccination as the period starting 14 days after receipt of the second dose and partial vaccination as the period starting 14 days after receipt of the first dose. Participants not meeting these criteria were considered unvaccinated. The partial vaccination model only included those who received one dose of the vaccine during the study period.